O1-17-4continuation of trastuzumab beyond progression for her2-positive advanced gastric cancer as second-line treatment
Yukiya Narita,Shigenori Kadowaki,Hiroya Taniguchi,Daisuke Takahari,Takashi Ura,Masashi Andoh,Yasumasa Niwa,Hiroki Hara,Kensei Yamaguchi,Kei Muro +9 more
1
TL;DR: Accumulating evidence supports the benefits of continuing trastuzumab (Tmab) beyond progression (TBP) in HER2-positive (HER2+) breast cancer patients, while its significance in Her2+ advanced gastric cancer (AGC) patients remains unclear.
read more
About: This article is published in Annals of Oncology. The article was published on 01 Oct 2014. and is currently open access. The article focuses on the topics: Combination chemotherapy.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Targeted therapies for gastric cancer: failures and hopes from clinical trials
TL;DR: This review will retrace the relevant clinical trials with molecular therapies performed in gastric cancer patients, discussing the possible reasons for their failure and indicating new perspective for a real improvement of the treatment of this disease.
References
Targeted therapies for gastric cancer: failures and hopes from clinical trials
TL;DR: This review will retrace the relevant clinical trials with molecular therapies performed in gastric cancer patients, discussing the possible reasons for their failure and indicating new perspective for a real improvement of the treatment of this disease.